Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.
Summary
In 106 patients with grade 1–2 ICI-related pneumonitis, a 6-week corticosteroid taper achieved higher 8-week treatment success than a 3-week taper, failing noninferiority and showing exploratory superiority. Severe adverse events were manageable and overall survival similar.
Key Findings
- 8-week treatment success was higher with 6-week vs 3-week taper (85.2% vs 66.7%).
- Noninferiority of the 3-week regimen was not demonstrated; exploratory analysis favored 6 weeks (P=0.013).
- Grade ≥3 adverse events were more frequent with 6 weeks (24% vs 12%) but were clinically manageable; overall survival did not differ.
Clinical Implications
Adopt a 6-week steroid taper for mild ICI-related pneumonitis to maximize short-term treatment success while monitoring for manageable adverse events.
Why It Matters
This is the first randomized trial to directly compare steroid taper durations in ICI-related pneumonitis and provides clear evidence to guide standard care.
Limitations
- Open-label design may introduce performance bias.
- Short-term (8-week) primary outcome; long-term relapse and steroid toxicity were not primary endpoints.
Future Directions
Evaluate relapse prevention, cumulative steroid toxicity, and oncologic outcomes with longer follow-up; explore steroid-sparing strategies and biomarkers to personalize taper duration.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Randomized controlled trial providing high-level evidence for treatment strategy.
- Study Design
- OTHER